About us

Pierre Courteille

Chairman of HealthTech For Care

Before being appointed President of the HealthTech For Care endowment fund (HTFC) in December 2023, Pierre Courteille significantly contributed to the fund as its co-founder, board member, and treasurer. Pierre brings over 25 years of experience in marketing… [read more]sales, and business development within the pharmaceutical industry, including 13 years based in Japan. In May 2023, Pierre was appointed Chief Business Officer. Prior to this role, he served as Chief Commercial Officer and Vice President of Business Development at Abivax. Before joining Abivax in April 2015, he was the Senior Vice President of sales and marketing for Guerbet, as well as the CEO of MEDEX (a medical devices company owned by Guerbet) starting in 2012. From 2009, Pierre served as the Vice President of Sales for Asia, Latin America, and EMEA, where he was responsible for the management of subsidiaries and agents, achieving the ambitious objective of optimizing commercial performance across these regions. As President of Guerbet Japan and Vice President for Guerbet Asia, Pierre successfully managed the rollout of its Japanese subsidiary and led the development of other branches in Asia. Pierre holds a pharmacy degree, a Master’s Degree in Company Management (IAE), a Master’s Degree in Biological and Medical Sciences, and an MBA with Honors from The University of Chicago Booth School of Business. He previously served as Vice President and Treasurer of France Biotech. Currently, he is the President of both the “Chicago Booth Alumni Club of France” and “The University of Chicago Alumni Association of France [/read]

Maryvonne Hiance

Honorary President of HealthTech For Care

Maryvonne Hiance graduated in 1972 from the École Polytechnique Féminine de Sceaux, and later from the Institut National des Sciences et Techniques Nucléaires de Grenoble In 1986, she moved to Nantes and played a key role in the creation of… [read more] Atlanpol an interregional competitiveness cluster covering the Pays de la Loire, Brittany, and Centre-Val de Loire regions. Within this framework, she redirected her professional path to focus on the valorization of new technologies in the field of health. For over 20 years, she led various innovative biotechnology companies.
In 2016, she assumed the presidency of France Biotech and, in this capacity, initiated the creation of the HealthTech Innovation Days (HTID) in 2019. In 2020, she took on the presidency of the HealthTech For Care endowment fund, whose mission is to accelerate the development of European health innovations to make them accessible to all patients. To date, Maryvonne has become the Honorary President of HealthTech For Care. [/read]

Elsy Boglioli

CEO at Bio-up

A healthcare advisory firm supporting companies in strong scale up or transformation phases, mainly in the field of cell and gene therapy. She has far-reaching expertise and a broad network within the pharma and medtech industries…[read more] Elsy created Bio-Up to combine her strategic expertise and her passion for solving operational challenges that typically face HealthTech companies. Her portfolio of activities allows her to fully leverage the wealth of her past experiences, including the coaching and sounding-board role she used to play as a BCG Partner and Managing Director.

Before she created Bio-Up, Elsy was Executive Vice President, Chief Operating Officer at Cellectis, a French biotechnology company focused on gene editing and its applications in oncology. At Cellectis she led various strategic and operational functions: strategy, business development, clinical trials program management, as well as manufacturing, with the objective of building in-house capacity.

Prior to joining Cellectis, Elsy worked at the Boston Consulting Group (BCG) for 12 years. She served as Partner and Managing Director in the Paris Office, was the leader of BCG’s biotech-focused business in Europe. She worked closely with biotech and pharma companies on topics such as specialty product launch optimization, partnering and M&A.

Elsy graduated from the Ecole Polytechnique in Paris, France and holds a master’s degree in economy and management from the Pompeu Fabra University in Barcelona, Spain. She also completed a College degree in Immuno-oncology at Institut Gustave Roussy in Paris, France.

In the past few years she was selected to be a Young Leader of the French American Foundation in 2018, was part of the Choiseul ranking of top Young French Economic Leaders (2019, 2020), and was among the Women’s Forum Rising Talents’ promotion of 2018. Beyond her work at Bio-Up, Elsy is passionate about education and sits on the Board of an International School, and she is also committed to helping women succeed in business. For example, as part of the Women2Women 8200 program, she mentors young women from the elite 8200 Israeli army unit. [/read]

Damien Catoir

Executive Vice President General Counsel and Corporate Secretary, Servier

Damien Catoir came aboard the Servier Group in April 2023, as Executive Vice President General Counsel and Corporate Secretary. He is a member of the Group Executive Committee… [read more] Damien Catoir has more than 15 years of experience in banking and in major law firms, both in France and in the United States. He joined the corporate world in 2018 within the Atos Group, where he was General Counsel and Secretary to the Board of Directors. As part of his missions, he guided Ajos in the negotiation of strategic partnerships, major contracts and significant M&A transactions. He also piloted complex litigations and important corporate reorganizations. Damien Catoir is a member of the New York and Paris bars. He holds a Master in Management from ESSEC Business School and studied cognitive psychology and neurosciences at École Normale Supérieure. He also holds a Master’s degree in General Private Law from University Paris 1 Panthéon-Sorbonne and a Juris Doctor degree from Cornell Law School.  [/read]

Marc Dechamps

CEO of Bioxodes

Biologist with extensive experience in the pharmaceutical industry dating back more than 35 years. During his career, he has worked for corporate pharma companies including GSK & ViiVHealthcare, building his expertise… [read more] in market development for new products, including infectious diseases, immunological disorders, oncology, CNS disorders and vaccines.
In 2016, Marc founded and became managing director of XMF consulting, a company which supports biotech and biopharma businesses with strategic advice and management leadership. He has also served as managing director of Delphi Genetics (CDMO) and interim CEO of eTheRNA Immunotherapies (mRNA biotech company). Marc is CEO of Bioxodes, a phase 2a clinical stage biotech company since October 22, serves as President of the board of Investsud Tech (group InvestSud) and board member of HealthTech for Care (HT4C). Marc is also co-academic Director for the newly created advanced masters in biotech & medtech ventures at the Solvay Brussels School of Economics & Management. [/read]

Christian Deleuze

COO for Innovation Sanofi & Chairman of Medicen Paris Region

From 2010 until October 2021, Christian Deleuze served as the General Manager of the Specialty Medicines Unit at Sanofi. On November 1, 2021, he assumed the role of Deputy General Manager for Innovation, reporting to…[read more] the President of Sanofi France, ensuring a strong relationship between the company and innovation ecosystems.
In May 2021, he became the President of Medicen Paris Région, the healthcare competitiveness cluster for the Île-de-France region. Since July 2023, he has also been the President of Enosis Santé, the association of healthcare competitiveness clusters. As the President of Campus Biotech Digital, he collaborates on the development of a globally competitive French bioproduction sector.
Since 2021, he has been involved in the planning and construction of an oncology Biocluster, the Paris Saclay Cancer Cluster (PSCC). Currently serving as the Treasurer of the PSCC foundation, he also presides over the PSCC Connect association, which brings together private economic actors in the cluster.
Christian Deleuze is also the President of the Healthcare Data Institute and serves as the Vice President of MERI. As a member of the Board of Directors of France Biotech for six years, he strives to facilitate dialogue among all players in innovation in France, ensuring that the use of resources and talents benefits patients and creates economic value in local communities. Representing France Biotech on the Board of the HealthTech For Care (HTFC), he is dedicated to enabling promising initiatives to access the resources and support needed for their development. [/read]

Jérôme Fabiano

Deputy Director, EIT Health France

Jérôme Fabiano has worked for more than 10 years in the health and health innovation sector in international positions. Holder of a master’s degree in international relations and European Affairs obtained at the Sorbonne… [read more] he has a double degree from the Skema Business School with a Master of Science in Management and Strategy as well as a Specialized Master’s degree in Knowledge Management and Competitive Intelligence.

He began his career at Axa in Life Insurance. He then joined a national health innovation cluster in Paris to provide a scientific, technological, and economic watch service to develop and finance innovative health projects and to support companies internationally, especially in the middle east and the US. He continued his career at Allianz Global Healthcare in the international affinity life insurance and reinsurance department. He now serves as Deputy Director at Eit Health France, an Horizon Europe funding Instrument of the European Commission gathering a community of 100 European and international organisations and which has invested more than 250 million euros, trained more than 70,000 people and accelerated more than 1,600 start-ups in innovation in health in Europe since its incorporation in 2016.[/read]

Eric Falcand

Pharma Executive

Eric Falcand has over 35 years’ experience in the pharmaceutical industry in General Management, Business Development and commercialization of Rx drugs in various Leadership positions at Synthelabo (now Sanofi) and Servier… [read more] He is currently the CEO of the Italian private pharmaceutical company Neopharmed Gentili and Board member of CYTEA BIO, a Swiss preclinical-stage biotech focusing on allogeneic cellular immunotherapies.[/read]

Frédéric Girard

Senior VP & Commercial Operations Europe at DBV Technologies

Doctor in Medicine and holder of a DESS in Business Administration, Frédéric Girard has worked for more than 30 years for the life sciences industry, in France and in different European countries. His experience covers a wide range of products…[read more] (innovative medicines, generic medicines, biosimilars, medical devices) and different types of companies (multinationals, family, SMEs, biotech). Frédéric Girard is today Senior Vice President, European Development Operations, for DBV Technologies.
Frédéric Girard is also Vice-President of France Biotech, where he leads the Market Access Working Group. France Biotech, founded in 1997, is an independent association which brings together healthcare innovation entrepreneurs and their expert partners.
Finally, Frédéric Girard is Foreign Trade Advisor, where he chairs the Health Expertise Group and the Mentoring Expertise Group. [/read]

Anaïs Le Corvec

Network Management at CEBR & Co-founder Cliclab

Specialist in international research and innovation management Anaïs Le Corvec is the CEO of Cliclab , a social innovation company O co-created in 2019. She has been the Managing director of the Council of European Bioregions, a network of Lifesciences Clusters in Europe, which she helped grow over the past 7 years…[read more]Her main interest is on Societal impact, transformative processes for companies, teams and people, ensuring our diverse society is represented in innovation and Research, as well as company developments and growth.
Anaïs also work as a consultant related to research assessment and project implementation. She worked in many different research fields such as Health, Information and Communication Technologies,  International Cooperation, and Innovation. She holds a Business Administration degree from the University of Montreal Business School HEC, with specialization in Marketing and International management. Established in Barcelona since 2001, she has been working as an International Research Advisor for the Vall d’Hebron Institute of Research, as a EU funded project managers for several entities like the University of Barcelona, the Fundacio Ciutat de Viladecans, and acted as Outreach coordinator for the European Science Open Forum ( ESOF). She also works as an expert reviewer for the European Commission in Research management related topics.[/read]

Philippe Monteyne

Partner at Aliath Bioventures

Dr. Philippe Monteyne MD, PhD is Partner of the VC Aliath Bioventures in Barcelona. Aliath aims to fund sustainable businesses that can create a significant impact on patients’ lives by providing new medical solutions and technologies that impact access, effectiveness and efficiency in the health sector…[read more] Philippe Monteyne has extensive and highly successful experience as a life sciences investor and pharmaceutical professional. Before joining Aliath, Philippe has been a Senior Partner of the private equity fund Fund+ in Belgium, having contributed to multiple investments including very profitable ones.
Philippe Monteyne is a Neurologist and holds a PhD in viral immunology from the Catholic University of Louvain and a postdoctoral degree in neuroimmunology from the Pasteur Institute in Paris.
Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012.
Amongst his achievements, was the development and launch of GSK’s Cervical Cancer Vaccine, Cervarix, the R&D work that allowed to develop Strimvelis and Tegsedi (gene therapy and oligonucleotide in rare diseases).
He also served as Vice President R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France “Les Entreprises du Médicament”​), of the Bioaster Insitute in Lyon, and of the « Fondation Plan Alzheimer France ».
He is a Board Director of several Biotech companies, in Belgium, France and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), and is part-time Professor and course coordinator of an Advanced Master in Biotech & MedTech Ventures at Solvay Management School, Brussels.[/read]

Cédric Moreau

Partner at Sofinnova Partners

Cedric Moreau is a Partner at Sofinnova Partners and a key member of the Crossover Strategy team. He joined the firm in June 2018, bringing 18 years of experience in life sciences investment banking….[read more]Prior to Sofinnova, Cedric was managing director and head of healthcare in the corporate finance department at Oddo BHF. In 2017, Oddo BHF was the top ranked firm for European biotech equity capital market deals. Prior to this, he was director at Bryan Garnier & Co where he completed several sizable cross-border transactions, including Galapagos, DBV, Ablynx, and Celyad. In total, he has managed more than 2 billion euros in European healthcare transactions. Cedric brings to the Sofinnova Crossover team and to his portfolio companies, a deep transactional expertise in the biopharma industry, as well as an extensive network of key opinion leaders, bankers and lawyers. Cedric was well known to the Sofinnova team before he came onboard, having executed several mandates for the firm’s portfolio companies. Before his corporate finance career, Cedric spent 10 years as a healthcare equity analyst, and was several times EXTEL top ranked (awarded for both individual and team performances) at Natixis and Fortis. He was in charge of coverage of listed biotech and pharma companies. Cedric holds a Master’s in Economics and post-graduate diploma in Finance and Taxation (Sorbonne) and diploma from the Société Française des Analystes Financiers (SFAF) [/read]

Christian Pierret

Former French Minister of Industry

Mr Pierret was the Minister in charge of Industry, Commerce, Crafts, Consumer Affairs (1997 / 2002 – Prime Minister L. Jospin and President of the Republic J. Chirac) , Member of the French Parliament, Deputy of the Vosges, Honorary Mayor of Saint-Dié-des-Vosges…[read more]
He is also Administrator of French biotechs companies but also  Legal and Financial Advisor for the European Program “European Processor Initiative”, group of French and German factories and research laboratories (since 2019).) [/read]

Christian Policard

Founding Partner at Biotech Development Conseils

Doctor in Biochemistry, who has traversed the spectrum of scientific and business leadership in the biomedical and biopharmaceutical arena. He has been Executive Vice-President and Executive Board Member of Sanofi… [read more] Director at Institut Pasteur, Founding Partner of Biotech Development Consulting and Chairman of Cellectis.
He is today Chairman of Theradiag and Panntherapi, Director and Treasurer of ATF/Technion, Senior Partner of Global Close Alliances, Senior Advisor of Vivalto Partners, Board Member of Vidac Pharma and Vice-President of HTFC. [/read]

Françoise Sellin

Consultant Patient Partner – President of Expertise-Patient

Françoise Sellin, who now defines herself as a patient-partner consultant, was diagnosed with cancer in 1998. She then left her job as a bookseller to dedicate herself to improving the healthcare journey and quality of life for patients and their caregivers… [read more]She is the driving force behind the creation of several regional and national patient support associations and recognized inter-associative events labeled by the Ministry of Health. She continues to be involved in the nonprofit sector and currently holds the position of vice-president of the Cancer Contribution association and project manager for a collective named GPS CANCER.

She served as co-chair of the first regional user committee in Brittany and, in that capacity, sat on various regional commissions. She has also participated in working groups at the French National Authority for Health (HAS) and the French National Cancer Institute (INCA).

In 2017, she enrolled in the Patients University at Sorbonne University and obtained a university diploma in “patient pathway support in oncology,” followed by a diploma in “health democracy” in 2018, and also pursued training in therapeutic patient education. In 2019, she decided to establish a health consulting agency, “Patient Expertise,” to support healthcare companies, startups, medical training centers, associations, healthcare facilities, and research centers in implementing projects aimed at improving healthcare pathways and outcomes. She is actively involved in France Biotech, where she currently serves on the board of directors and co-coordinates the “Patient Caregiver Family Caregiver” working group. Additionally, she assists the Paris Saclay Cancer Cluster in managing its patient committee.

Françoise Sellin’s numerous past and present activities have enabled her to acquire a deep understanding of the healthcare ecosystem and a broad network, particularly comprising patient partners with whom she collaborates on various missions. [/read]

The involvement of the HTFC international independent experts board members through working groups aim to accelerate care for the patient: